SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus
April 20, 2015 08:45 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., April 20, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2015 20:45 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Announces Proposed Public Offering of Common Stock
April 13, 2015 16:28 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., April 13, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced that it has commenced an underwritten public offering of $100 million of shares of its common...
SAGE Therapeutics Announces Presentations at Upcoming Scientific Conferences
April 09, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., April 9, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in Mid-2015
April 02, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., April 2, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
February 27, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Feb. 27, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Appoints New Vice Presidents to Lead Key Organizational Functions
February 13, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Feb. 13, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Announces Participation in February Conferences
January 28, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Jan. 28, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Initiates Phase 2a Trial of SAGE-547 in Postpartum Depression
January 12, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial and Emergency Use Program of SAGE-547 in Patients With Super-Refractory Status Epilepticus
January 09, 2015 06:30 ET
|
SAGE Therapeutics
Greater Than 70 Percent Response Rate Observed in Two Patient Groups
Data Reinforce Clinical Activity and Safety Profile Demonstrated by SAGE-547
Phase 3 Pivotal Trial Expected to Begin by...